Citations

Clear

400 citation(s) found for "Berry, DA".

Thoracic Lymphangiomas, Lymphangiectasis, Lymphangiomatosis, and Lymphatic Dysplasia Syndrome
Faul, John L. , Colby, Thomas V. , Ruoss, Stephen J. , WALTER, MATTHEW B., Raffin, Thomas A., Berry, Gerald J. , Rosen, Glenn D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 161 | Issue: 3 | Pages: 1037-1046

10.1164/ajrccm.161.3.9904056 | PMID 10712360 Get It

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
Berry, Donald A. , Zujewski, JoAnne, Hunsberger, Sally , Rubinstein, Larry , Tomaszewski, Joseph E. , Kelloff, Gary, Perlmutter, Jane , Buxton, Meredith , Lyandres, Julia, Albain, Kathy S. , Benz, Chris, Chien, A. Jo , Haluska, Paul , Leyland‐Jones, Brian , Liu, Minetta C. , Olopade, Olufunmilayo I. , Park, John W., Parker, Barbara A. , Yee, Douglas , DeMichele, Angela , Zujewski, Jo Anne , Münster, Pamela N. , Pusztai, Lajos , Tripathy, Debu , Rugo, Hope S. , Esserman, Laura J. , Olopade, Olufunmilayo I , Yee, Douglas , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | March 8, 2013 | Volume: 19 | Issue: 11 | Pages: 2817-2823

10.1158/1078-0432.ccr-12-2620 | PMID 23470967 Get It

Abstract New approaches to drug development are critically needed to lessen the time, cost, and resources necessary to identify and optimize active agents. Strategies to accelerate drug development include testing drugs earlier in the disease process, such as the neoadjuvant setting. The U.S. Food and Drug Administration (FDA) has issued guidance designed to accelerate drug approval through the use of neoadjuvant studies in which the surrogate short-term endpoint, pathologic response, can be used to identify active agents and shorten the time to approval of both efficacious drugs and biomarkers identifying patients most likely to respond. However, this approach has unique challenges. In particular, issues of patient safety are paramount, given the exposure of potentially curable patients to investigational agents with limited safety experience. Key components to safe drug development in the neoadjuvant setting include defining a study population at sufficiently poor prognosis with standard therapy to justify exposure to investigational agents, defining the extent and adequacy of safety data from phase I, detecting potentially harmful interactions between investigational and standard therapies, improving study designs, such as adaptive strategies, that limit patient exposure to ineffective agents, and intensifying safety monitoring in the course of the trial. The I-SPY2 trial is an example of a phase II neoadjuvant trial of novel agents for breast cancer in which these issues have been addressed, both in the design and conduct of the trial. These adaptations of phase II design enable acceleration of drug development by reducing time and cost to screen novel therapies for activity without compromising safety. Clin Cancer Res; 19(11); 2817–23. ©2013 AACR.
Hip and knee arthroplasty 2011
Rosenberg, Aaron G., Berend, Michael E. , Berry, Daniel J. , Valle, Craig J. Della , MacDonald, Steven J. , Minas, T., Berry, Daniel J

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | November 1, 2012 | Volume: 94-B | Issue: 11_Supple_A | Pages: 157-166

10.1302/0301-620x.94b11.30511 | PMID 23118407 Get It

This conversation represents an attempt by several arthroplasty surgeons to critique several abstracts presented over the last year as well as to use them as a jumping off point for trying to figure out where they fit in into our current understanding of multiple issues in modern hip and knee arthroplasty.
Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101
Cirrincione, Constance, Berry, Donald A. , Becker, Heather P., Perez, Edith A. , Martino, Silvana, Atkins, James N., Kimmick, Gretchen , Norton, Larry , Muss, Hyman B. , Hudis, Clifford A. , Shulman, Lawrence N. , O'Regan, Ruth M , Mayer, Erica L. , Schneider, Charles John , Winer, Eric P. , Norton, Larry

Mayo Clinic

Journal of Clinical Oncology | July 24, 2012 | Volume: 30 | Issue: 33 | Pages: 4071-4076

10.1200/jco.2011.40.6405 | PMID 22826271 Get It

PurposeThe ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also sought to determine whether paclitaxel (T) is as efficacious as doxorubicin/cyclophosphamide (AC), but with reduced toxicity.Patients and MethodsBetween 2002 and 2008, the study enrolled women with operable breast cancer and zero to three positive nodes. Patients were randomly assigned to either four or six cycles of either AC or T. Study stratifiers were estrogen receptor/progesterone receptor (ER/PgR), human epidermal growth factor receptor 2 (HER2), and menopausal status. After 2003, all treatment was administered in dose-dense fashion. The primary efficacy end point was relapse-free survival (RFS).ResultsA total of 3,171 patients were enrolled; 94% were node-negative and 6% had one to three positive nodes. At a median follow-up of 5.3 years, the 4-year RFS was 90.9% and 91.8% for six and four cycles, respectively. The adjusted hazard ratio (HR) of six to four cycles regarding RFS was 1.03 (95% CI, 0.84 to 1.28; P = .77). The 4-year OS was 95.3% and 96.3% for six and four cycles, respectively, with an HR of six to four cycles of 1.12 (95% CI, 0.84 to 1.49; P = .44). There was no interaction between treatment duration and chemotherapy regimen, ER/PgR, or HER2 status on RFS or OS.ConclusionFor women with resected primary breast cancer and zero to three positive nodes, we found no evidence that extending chemotherapy regimens of AC or single-agent T from four to six cycles improves clinical outcome.
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology
Darragh, Teresa M. , Colgan, Terence J. , Cox, J. Thomas, Heller, Debra S. , Henry, Michael , Luff, Ronald D., McCalmont, Timothy H. , Nayar, Ritu , Stoler, Mark H. , Wilkinson, Edward J., Zaino, Richard J., Wilbur, David C. , Luff, Ronald D., Wilkinson, Edward J., Wilkinson, Edward J., O’Connor, Dennis M., Reynolds, R. Kevin, Selim, M. Angélica , Scurry, James , Chelmow, David , Howell, Lydia, Ronnett, Brigitte M., Waxman, Alan G., Haefner, Hope K. , Leslie, Kieron , Lytwyn, Alice, Winkler, Barbara , Colgan, Terence J., Downs, Levi S., Laucirica, Rodolfo, Allbritton, Jill, Ioffe, Olga B. , Joste, Nancy E., Berry, J. Michael, Lin, Oscar , Welton, Mark L., Otis, Christopher N. , Stoler, Mark H. , Bentz, Joel S., Quade, Bradley J. , Schwartz, Mary R. , Luff, Ronald D., Castle, Philip E. , García, Francisco , Moriarty, Ann , Niedt, Greg , Carter, Alicia , Neal, Margaret B., Reddy, Vijaya , Robboy, Stanley J. , Spires, Susan E., Luff, Ronald D., Palefsky, Joel Michael , Wilkinson, Edward J., Wilkinson, Edward J., Shea, Christopher Michael , Staats, Paul N. , Roberts, Jennifer Margaret , Colgan, Terence J., Kong, Christina S. , Luff, Ronald D., Duggan, Máire A. , Goodman, Marc T. , Saraiya, Mona , Silverberg, Steven M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 28, 2012 | Volume: 136 | Issue: 10 | Pages: 1266-1297

10.5858/arpa.lgt200570 | PMID 22742517 Get It

Abstract The terminology for human papillomavirus (HPV)–associated squamous lesions of the lower anogenital tract has a long history marked by disparate diagnostic terms derived from multiple specialties. It often does not reflect current knowledge of HPV biology and pathogenesis. A consensus process was convened to recommend terminology unified across lower anogenital sites. The goal was to create a histopathologic nomenclature system that reflects current knowledge of HPV biology, optimally uses available biomarkers, and facilitates clear communication across different medical specialties. The Lower Anogenital Squamous Terminology (LAST) Project was cosponsored by the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology and included 5 working groups; 3 work groups performed comprehensive literature reviews and developed draft recommendations. Another work group provided the historical background and the fifth will continue to foster implementation of the LAST recommendations. After an open comment period, the draft recommendations were presented at a consensus conference attended by LAST work group members, advisors, and representatives from 35 stakeholder organizations including professional societies and government agencies. Recommendations were finalized and voted on at the consensus meeting. The final, approved recommendations standardize biologically relevant histopathologic terminology for HPV-associated squamous intraepithelial lesions and superficially invasive squamous carcinomas across all lower anogenital tract sites and detail the appropriate use of specific biomarkers to clarify histologic interpretations and enhance diagnostic accuracy. A plan for disseminating and monitoring recommendation implementation in the practicing community was also developed. The implemented recommendations will facilitate communication between pathologists and their clinical colleagues and improve accuracy of histologic diagnosis with the ultimate goal of providing optimal patient care.
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
Lee, J.-M., Ramos, E.M., Lee, J.-H., Gillis, Tammy , Mysore, Jayalakshmi Srinidhi, Hayden, Michael R. , Warby, Simon C. , Morrison, PJ, Nance, Martha , Ross, Christopher A. , Margolis, Russell L. , Squitieri, Ferdinando , Orobello, S., Donato, Stefano Di , Gómez‐Tortosa, Estrella , Ayuso, Carmen , Suchowersky, Oksana , Trent, R J, McCusker, Elizabeth, Novelletto, Andrea , Frontali, Marina , Jones, Randi, Ashizawa, Tetsuo , Saint‐Hilaire, Marie , Hersch, Steven M. , Rosas, H. Diana , Lucente, Diane , Harrison, Madeline, Zanko, Andrea, Abramson, Ruth K., Marder, Karen, Sequeiros, Jorge , Paulsen, Jane S. , Landwehrmeyer, G. Bernhard , Myers, Richard H. , MacDonald, Marcy E., Gusella, James F. , Frati, Luigi, Perlman, Susan B. , Conneally, P. M., Klimek, Mary Lou, Diggin, Melissa, Hadzi, Tiffany C., Duckett, Ayana, Ames, David, Anderson, Christine, Anderson, Karla J., Anderson, Karen, Andrews, Thomasin, Axelson, Eric, Aylward, Elizabeth , Barker, Roger A. , Barth, Katrin, Barton, Stacey K. , Baynes, Kathleen, Bea, Alexandra, Beglinger, Leigh J., Biglan, Kevin , Björk, K., Blanchard, Steve, Bockholt, Jeremy , Bommu, Sudharshan Reddy, Brossman, Bradley G., Burrows, Maggie, Calhoun, Vince D. , Carlozzi, Noelle E. , Chesire, Amy M., Chiu, Edmond, Connell, R.J., Connor, Carmela, Corey‐Bloom, Jody , Craufurd, David, Cross, Stephen, Santos, Rachelle Dar, Davis, Jennifer , Decolongon, Joji, Dipietro, A., Doucette, Nicholas, Downing, Nancy R. , Dudler, Ann, Ecker, Daniel, Erickson, Diane, Erwin, Cheryl , Farias, Sarah Tomaszewski , Fatas, Marta, Fullam, Ruth, Furtado, Sarah , Garde, Mónica Bascuñana, Geschwind, Michael D., Gooblar, Jon, Goodman, Anna , Griffith, Jane, Groves, Mark, Guttman, Mark, Hamilton, Joanne M., Harris, Greg, Heaton, Robert K. , Helmer, Karl, Henneberry, Machelle, Herwig, Kelly, Howard, Elizabeth, Hunter, Christine , Jankovic, Joseph, Johnson, Hans J. , Johnson, Arik, Jones, Kathy, Kimble, Mycah, King, Pamela, Klöppel, Stefan , Komiti, Angela , Kumar, Rajeev , Leavitt, Blair, Leserman, Anne, Lipe, Hillary, Lowe, Mark J. , Magnotta, Vincent A. , Mallonee, William, Mans, Nicole , Marietta, Jacquie, Marshall, Frederick J., Mason, Sarah, Matheson, Kirsty, Matson, Wayne R., McDowell, William , Miedzybrodzka, Zosia , Mills, James A. , Miracle, Dawn, Montross, Kelsey, Moore, David D. , Mori, S., Moskowitz, Carol, Newman, Emily R., Novak, Marianne, O’Rourke, Justin J. F., Oakes, David , Ondo, William G. , Orth, Michael, Pease, Karen R., Perlmutter, Joel, Peterson, Asa , Pierson, Ron, Preston, J. Samuel, Quaid, Kimberly A., Radtke, Dawn, Rae, D. O., Raymond, Lynn A. , Reading, Sarah, Ready, Rebecca E. , Reece, Christine, Reynolds, Norm, Richardson, Kylie, Rickards, Hugh , Ro, Eunyoe , Rodnitzky, Robert L., Rosser, Elisabeth, Rosser, Anne, Price, Kathy, Price, Kathy, Ryan, Pat, Salmon, David P. , Samii, Ali, Schumacher, Jamy, Sendon, Jose Luis Lópenz, Shear, Paula K. , Sheinberg, Alanna, Shpritz, Barnett, Simpson, Sheila A., Singer, Adam D. , Smith, Megan M. , Snyder, Pete, Song, Allen W. , Sran, Satwinder, Stober, Janice, muth, Sigurd Sü, Suter, Greg, Tabrizi, Sarah J. , Tempkin, Terry, Thompson, Sean , Thomsen, Teri, Thumma, Kelli, Trautmann, Sonja, Tremont, Geoff, Turner, Jessica A. , Uc, Ergun, Duijn, E. van, Walsem, Marleen van, Vik, Stacie , Vonsattel, Jean Paul, Vuletich, Elizabeth J., Warner, Tom, Wasserman, Paula, Waterman, Elijah, Weaver, Kurt E. , Weir, David , Werling-Witkoske, Chris, Wesson, Melissa, Westervelt, Holly James , Weydt, Patrick , Wheelock, Vicki, Wodarski, Mary, Wojcieszek, Joanne, Wood, Jessica, Wood‐Siverio, Cathy, Wu, Shuhua , Yastrubetskaya, Olga, Yébenes, Justo García de, Zhao, Yong Qiang, Zimbelman, Janice L., Zschiegner, Roland, Aaserud, Olaf, Abbruzzese, Giovanni , Andrews, Thomasin, Andrich, Jurgin, Antczak, Jakub , Arran, Natalie, Artiga, María José Saiz, Bachoud‐Lévi, Anne‐Catherine , Banaszkiewicz, Krysztof, Barberá, Miguel Aguilar, Barrero, Francisco Javier , Bas, Jordi, Beister, Antoine, Bertini, Elisabetta, Biunno, Ida , Bjørgo, Kathrine, Bjørnevoll, Inga, Bohlen, Stefan, Bonelli, Raphael M., Bos, Reineke, Bourne, Colin, Bradbury, Alyson, Brockie, Peter, Brown, Felicity, Buck, Andrea, Burg, Sabrina, Burgunder, Jean‐Marc , Burns, Peter, Burrows, Liz, Calopa, Matilde , Carruesco, Gemma Tome, Casado, Ana Gonzalez, Catena, Judit López, Chu, Carol , Clapton, Jackie, Clayton, Carole, Clenaghan, Catherine, Connemann, Julia, Crooks, Jenny, Cubillo, Patricia Trigo, Cubo, Esther , Curtis, Adrienne, Michele, Giuseppe De , Souza, Jenny de, Weert, A. Marit de, Dekker, M., Descals, Asunción Martínez, Maio, Luigi Di, Pietro, Anna Di, Dipple, Heather, Dose, M., Dumas, Eve M., Dunnett, Stephen B. , Elifani, Francesca , Ellison-Rose, Lynda, Elorza, Marina D., Eschenbach, Carolin, Evans, Carole, Fairtlough, Helen, Fannemel, Madelein, Fenollar, María del Mar, Ferrandes, Giovanna, Ferreira, Jaoquim J., Fillingham, Kay, Finisterra, Ana Maria, Fisher, Kate , Fletcher, Amy, Foster, Jillian, Foustanos, Isabella, Frech, Fernando Alonso, Fullam, Robert, Fullham, Ruth, Gago, Miguel , García, R. de Francisco, García, Socorro S., Garrett, Carolina, Gellera, Cinzia , Gill, Paul R., Ginestroni, Andrea, Golding, Charlotte, Gørvell, Per F., Griguoli, Anna Maria, Gross, Diana, BascuñanaGuerra, Monica, Guerra, Maria Rosália, Guerrero, Rosa , Guía, D. Badenes, Guidubaldi, Arianna, Hallam, Caroline, Hamer, Stephanie, Hammer, K., Handley, Olivia, Harding, Alison, Hasholt, Lis, Hedge, R.M., Heiberg, Arvid, Heinicke, Walburgis, Held, Christine, Hernanz, Laura Casas, Herranhof, Briggitte, Hiivola, Heli, Hjermind, Lena E. , Hobson, Emma, Hoffmann, Rainer , Holl, Anna, Howard, Liz Livingston, Huson, Susan, Ialongo, Tàmara, Idiago, Jesús Miguel Ruiz, Illmann, Torsten, Jachińska, Katarzyna, Jacopini, Gioia, Jakobsen, Oda, Jamieson, Stuart W., Jamrozik, Zygmunt , Janik, Piotr , Johns, Nicola, Jones, Lesley , Jones, Una , Jurgens, Caroline K., Kaelin‐Lang, Alain , Kershaw, Ann, Kieni, Janina, Koivisto, Susana Pro, Koppers, Kerstin, Kosinski, Christoph M., Kremer, Berry, Krysa, Wioletta, Kwieciński, Hubert, Lahiri, Nayana , Lambeck, Johann , Lange, Herwig W. , Laver, Fiona, Levey, Jamie, Leythaeuser, Gabriele, Lezius, Franziska , Llesoy, Joan Roig, Löhle, Matthias , López, Cristobal Diez-Aja, Lorenza, Fortuna, Loria, G, Magnet, Markus, Mandich, Paola , Mariotti, Caterina , Mariscal, Natividad, Marková, Ivana S. , Marquard, Ralf, Martikainen, Kirsti, Martínez, Isabel Haro, Martínez‐Descals, Asunción, Martino, T., Mason, Sarah, McKenzie, Sue, Mechi, Claudia, Middleton, Julia, Milkereit, Eva, Miller, Julie, Minster, Sara, Möller, Jens Carsten , Monza, Daniela, Morales, Blas, Moreau, Laura V., Murch, Ann, Niess, Anke, Nørremølle, Anne , O'Donovan, Kristy, Orth, Michael, Otti, Daniela, Padieu, Hélène, Paganini, M. , Painold, Annamaria , Päivärinta, Markku, Partington-Jones, Lucy, Paterski, Laurent, Paterson, Nicole D., Patino, Dawn Freire-, Patton, Michael J. , Peinemann, Alexander, Peppa, Nadia , Perea, María Fuensanta Noguera, Peterson, Maria, Càrdenas, Regina Pons i, Prehn, Christian, Price, Kathleen, Probst, Daniela, Quiroga, Purificacion Pin, Raab, Tina, Rakowicz, Maryla, Raman, Ashok, Raymond, Lucy, Reinante, Gema, Retterstøl, Lars, Ribaı̈, Pascale, Riballo, Antonio Villa, Ribas, Guillermo García, Rinaldi, Carlo , Rissling, Ida, Rivera, Susana Vázquez , Robert, Misericordia Floriach, Roca, Elvira, Romano, Silvia , Romoli, Anna Maria , Roos, Raymond A.C., Røren, Niini, Rosser, Anne, Rossi, F., Rothery, Jean, Ruíz, Belan Garzon, Russo, Cinzia Valeria , Ryglewicz, Danuta , Saft, Carston, Sánchez, Vicenta , Sando, Sigrid Botne , Šašinková, Pavla, Saß, Christian, Scheibl, Monika, Schiefer, Johannes, Schlangen, Christiane, Schöggl, Helmut, Schrenk, Caroline, Schüpbach, Michaël , Schuierer, Michele, Sebastián, Ana Rojo, Selimbegovic-Turkovic, Amina, Sempołowicz, Justyna, Silva, Mark, Sławek, Jarosław , Snowden, Julie S. , Soleti, Francesco, Sollom, Andrea, Sołtan, Witold, Sorbi, Sandro , Sørensen, Sven Asger, Spadaro, M., Städtler, Michael, Stamm, Christiane, Steiner, Tanja, Stokholm, Jette, Stokke, Bodil, Storch, Alexander , Straßburger, Katrin, Stubbe, Lars, Szczudlik, Andrzej, Taylor, Rachel , Terol, Santiago Duran-Sindreu, Thomas, Gareth, Thomson, Aileen, Tidswell, Katherine, Torres, María Martirio Antequera, Toscano, Jean, Townhill, Jenny, Tucci, Tecla, Tuuha, Katri, Uhrová, Tereza , Valadas, Anabela , Hout, Monique S.E. van, Oostrom, Joost C.H. van, Vugt, Jeroen P.P. van, vanm, Walsem Marleen R., Vandenberghe, Wim , Verellen‐Dumoulin, Christine, Vergara, M, Verstappen, C.C.P., Verstraelen, Nichola , Viladrich, Cèlia Mareca, Villanueva, Clara , Wahlström, Jan , Wehus, R., Weindl, A., Westmoreland, Leann, Wiedemann, Alexandra, Wild, Edward J. , Wild, Sue, Witjes‐Ané, Marie‐Noëlle W. , Witkowski, Grzegorz , Wójcik-Pędziwiatr, Magdalena , Wolz, Martin , Wolz, Annett, Wright, Jan, Yardumian, Pam, Yates, Shona, Yudina, Elizaveta, Zaugg, Sabine Weber, Zdzienicka, Elżbieta, Zielonka, Euginiusz, Zinzi, Paola , Zucker, B., Adams, John , Antonijevic, Irina , Beck, Christopher A. , Chiu, Edmond, Churchyard, Andrew, Colcher, Amy, Dorsey, Ray, Drazinic, Carolyn, Dubinsky, Richard , Duff, Kevin, Giuliano, Joe, Greenamyre, Timothy, Jennings, Dana, Kang, Un Jung , Kumar, Rajeev, Leavitt, Blair, LeDoux, Mark S. , Mohlo, Eric, Morgan, John C. , Panisset, Michel , Perlmutter, Joel, Revilla, Fredy J., Robertson, Suzanne, Robottom, B., Scott, B.L. , Shoulson, Ira , Singer, Carlos , Tabbal, Samer D., van, Kammen Dan, Vetter, Louise, Walker, Francis O. , Warner, John Harley , Weiner, illiam, Broyles, Janice, Clouse, Ronda, Coleman, Allison, Davis, Robert E. , de-la-Rosa, J.-L., Deuel, Lisa M., Dietrich, Susan, Dubinsky, Hilary, Eaton, Ken, Erickson, Diane, Fitzpatrick, Mary Jane, Frucht, Steven J. , Gartner, Maureen, Goldstein, Jody, Hickey, Charlyne, Hunt, Victoria, Jaglin, Jeana, Lindsay, Pat, Louis, Elan D. , Loy, Clemet, Lucarelli, N., Malarick, Keith, Martin, Amanda, McInnis, Robert , Nucifora, Frederick C. , Palao, Alicia, Peavy, Guerry M. , Quesada, Mónica, Schmidt, Amy P., Segro, Vicki, Sperin, Elaine, Tanev, Kalo, Tempkin, Teresa, Thiede, Curtis, Zauber, Elizabeth, Ferreira, Joaquim J. , Vivancos, L. , Frank, Samuel , Dürr, Alexandra , Rosenblatt, Adam E , Ahmed, Anwar E. , Allen, Paul D. , Anderson, Christine, Ashburner, John , Beall, Erik B. , Beg, Mirza Faisal , Calhoun, Vince D. , Chua, Phyllis M-L. , Cysique, Lucette A. , Dunn, Steve , Epping, Eric A. , Evans, Kenneth , Factor, Stewart Alan , Fiedorowicz, Jess G. , Gehl, Carissa , Goh, Anita , Gooblar, Jonathan, Harrington, Deborah Lynn , Hershey, Tamara G. , Jankovic, Joseph, Johnson, Arik, Juhl, Andrew R. , Kim, Eun Young , Koenig, Katherine A. , Langbehn, Douglas R. , Leavitt, Blair, Lim, Kelvin O. , Martin, W. R. Wayne , Mason, Sarah, Mazzoni, Pietro , Miller, Michael I. , Moser, David J. , Nopoulos, Peg , Orth, Michael, Panegyres, Peter K. , Perlmutter, Joel, Phillips, Michael , Potkin, Steven G. , Rao, Stephen M. , Reilmann, Ralf , Robinson, Robert A. , Rogers, Benedict D. , Rosser, Anne, Price, Kathy, Price, Kathy, Schumacher, Jessica R. , Siedlecki, Karen L. , Smith, Jim Q. , Smith, Glenn E. , Stephan, Klaas Enno , Testa, Claudia M. , Toga, Arthur W. , Uc, Ergun, Vaccarino, Anthony L. , Warner, Tom, Wassink, Thomas H. , Welsh, Claire E. , Williams, Kent C. , Williams, Janet K. , Wood, Jessica, Andrews, Thomasin, Poggio, M. , Bandmann, Oliver , Bentivoglio, Anna Rita , Bruno, Stefania , Bryl, Anna , Busquets, Núria , Busse, Monica E , Ciesielska, Anna , Coelho, Miguel M , Nicola, Antonio De , Fannemel, Madeleine , Fasano, Alfonso , Grant, Janet F. , Guedes, Leonor Correia , Herranhof, Brigitte, Herrera-Espiñeira, Carmen , Hidding, Ute , Hill, Susan , Hunt, Sarah E , Kalbarczyk, Anna , Khalil, Hanan W. , Klimberg, Aneta , Krawczyk, Małgorzata Anna , Kremer, Berry P. H., Leenders, Klaus Leonhard , Marchese, Roberta , Marcinkowski, T , Mason, Sarah, Mendes, Tiago , Mestre, Tiago , Miller, J. Philip , Moreau, Laura V., López-Sendón, José Luis , Münchau, Alexander Maximilian , Nielsen, Jørgen Erik , Orth, Michael, Owen, Michael J. , Freire-Patino, Dawn, Piacentini, Silvia , Piano, Carla , Quarrell, Oliver , Rakowicz, Maryla, Reisinger, Karin M. , Richter, Sven , Ritchie, Stuart James , Rose, Sarah , Rosser, Anne, Rudzińska, Monika , Ruiz, Pedro , Saft, Carston, Salvatore, Elena , Schmidt, Simone Bianca , Sitek, Emilia J. , Soliveri, Paola , Stopford, Cheryl L. , Sułek, Anna , Thompson, J. C. , Warner, Thomas T. , Werner, Cornelius Johannes , Zaremba, Jacek , Zielonka, Daniel , Zittel, Simone , Agarwal, Pinky , Chiu, Edmond, Duff, Kevin, Foroud, Tatiana , Greenamyre, Timothy, Higgins, Donald S. , Kostyk, Sandra K. , Kumar, Rajeev, Leavitt, Blair, Perlmutter, Joel, Sanchez‐Ramos, Juan , Shannon, Kathleen M. , Erickson, Diane, Muratori, Lisa M. , O’Neill, Christine J. , Turner, Jessica A , Ross, Christopher A , Ferreira, Joaquim J , Sławek, Jarosław , Magnotta, Vincent A

Mayo Clinic

Neurology | February 9, 2012 | Volume: 78 | Issue: 10 | Pages: 690-695

10.1212/wnl.0b013e318249f683 | PMID 22323755 Get It

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Lara, Jonathan F. , Thor, Ann D. , Dressler, Lynn G., Broadwater, Gloria , Bleiweiss, Ira J. , Edgerton, Susan M., Cowan, David P., Goldstein, Lori J. , Martino, Silvana, Henderson, I. Craig, Norton, Larry , Hudis, Clifford A. , Berry, Donald A. , Hayes, Daniel F. , B, for the Cancer and Leukemia Group, Ingle, James N. , Winer, Eric P. , Ellis, Matthew J. , B, for the Cancer and Leukemia Group, Norton, Larry

Mayo Clinic

Clinical Cancer Research | June 21, 2011 | Volume: 17 | Issue: 15 | Pages: 5170-5178

10.1158/1078-0432.ccr-11-0484 | PMID 21693655 Get It

Abstract Purpose: p53 as a prognostic and predictive factor in early-stage breast cancer has had mixed results. We studied p53 protein expression, by immunohistochemistry, in a randomized clinical trial of stage II patients treated with adjuvant doxorubicin and cyclophosphamide with or without paclitaxel [Cancer and Leukemia Group B (CALGB) 9344, INT0148]. Patients and Methods: Epithelial p53 expression was evaluated using two immunohistochemical antibodies (DO7 and 1801) in formalin-fixed, paraffin-embedded tissue from patients with node-positive breast cancer who were randomized to four cycles of cyclophosphamide and one of three doses of doxorubicin (60, 75, or 90 mg/m2; AC) and to receive four subsequent cycles of paclitaxel (T) or not. Prognostic and predictive value of p53 protein expression was assessed, independent of treatment assignment, for escalating doses of doxorubicin or addition of T with endpoints of relapse-free (RFS) and overall survival (OS). Results: Of 3,121 patients, 1,887 patient specimens treated on C9344 were obtained, passed quality control, and evaluated for p53 expression. Expression was 23% and 27% for mAbs 1801 and D07, respectively, with 92% concordance. In univariate analysis, p53 positivity was associated with worse OS with either antibody, but only p53 staining with monoclonal antibody 1801 had significantly worse RFS. In multivariate analysis, p53 was not predictive of RFS or OS from either doxorubicin dose escalation or addition of paclitaxel regardless of the antibody. Conclusion: Nuclear staining of p53 by immunohistochemistry is associated with worse prognosis in node-positive patients treated with adjuvant doxorubicin-based chemotherapy but is not a useful predictor of benefit from doxorubicin dose escalation or the addition of paclitaxel. Clin Cancer Res; 17(15); 5170–8. ©2011 AACR.
Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium.
Berry, Donald A. , Goetz, Matthew P. , Klein, Teri E.

Mayo Clinic

Cancer Research | December 30, 2010 | Volume: 69 | Issue: 24_Supplement | Pages: 33-33

10.1158/0008-5472.sabcs-09-33 Get It

Abstract Background: An estimated 1.3 million women worldwide will be diagnosed this year with early stage breast cancer. The majority of women have estrogen receptor (ER) positive breast cancer and are candidates for endocrine therapy. Tamoxifen remains the most commonly employed agent worldwide and substantially reduces recurrence and mortality. Tamoxifen is a pro-drug. CYP2D6 converts tamoxifen to endoxifen, which is primarily responsible for inhibition of estrogen-stimulated breast cancer growth in vitro. There have been conflicting reports regarding the relationship between CYP2D6 genotype/phenotype and tamoxifen clinical outcome. The ITPC was established to collect the worldwide experience relating to genetic variation in CYP2D6 and the outcomes of women with ER positive breast cancer treated with adjuvant tamoxifen. Establishment of the predictive value of CYP2D6 would enable the a priori identification of patients that could be spared ineffective therapy.Methods: Individual patient data including tumor characteristics, genotype, medication data, and recurrence information were requested from all published and non-published reports of clinical outcomes related to CYP2D6 and deposited at PharmGKB. CYP2D6 genotype was available for the following null (*3, 4, 5 and 6) and IM (*10, 17 and 41) alleles. CYP2D6 inhibiting medication data was requested for weak and potent CYP2D6 inhibitors. The primary analysis was to determine the association of CYP2D6 phenotype (combined genotype and medication) with breast cancer recurrence in tamoxifen treated early stage, ER positive invasive breast cancer.Results: At this time, the ITPC has received patient data on 3432 patients from the U.S., Sweden, UK, Germany, Belgium, and Japan. Median age at diagnosis was 62 years. CYP2D6 genotype was available in 3,392 (99%). The allele frequency for CYP2D6*4, the most common allele associated with the CYP2D6 poor metabolizer phenotype, was q=0.23. A total of 1152 recurrences representing first events (either local, regional, distant, or contralateral breast cancer) were recorded. At the time of abstract submission, patient and genotype data from an additional 1300 tamoxifen treated patients were pending submission.Conclusions: The ITPC represents the largest collection of individual patient data in regard to the potential importance of CYP2D6 phenotype in adjuvant tamoxifen therapy. The findings from this consortium are expected to substantially improve the global understanding of CYP2D6 and tamoxifen clinical outcome. Final results will be presented at the meeting Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 33.
Total Hip Arthroplasty with Shortening Subtrochanteric Osteotomy in Crowe Type-IV Developmental Dysplasia
Krych, Aaron J. , Howard, James L. , Trousdale, Robert T. , Cabanela, Miguel E., Berry, Daniel J. , Krych, Aaron J , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | September 15, 2010 | Volume: 92 | Issue: Supplement_1_Part_2 | Pages: 176-187

10.2106/jbjs.j.00061 | PMID 20844173 Get It

BACKGROUND: When surgeons perform total hip arthroplasty for hips with a high dislocation related to developmental dysplasia of the hip, obtaining long-term stable implant fixation and optimizing patient function remain challenges. The purpose of this paper was to evaluate the results of cementless arthroplasty with a simultaneous subtrochanteric shortening osteotomy in a group of patients with Crowe type-IV developmental dysplasia of the hip. METHODS: In a retrospective study, we evaluated the results and complications of twenty-eight consecutive primary cementless total hip arthroplasties in twenty-four patients (twenty women and four men), all of whom had Crowe type-IV developmental dysplasia of the hip. The arthroplasty was performed in combination with a subtrochanteric shortening osteotomy and with placement of the acetabular component at the level of the anatomic hip center. The patients were evaluated at a mean of 4.8 years postoperatively. RESULTS: The mean Harris hip score increased from 43 points preoperatively to 89 points at the time of final follow-up (p < 0.01). Twelve (43%) of the twenty-eight hips had an early or late complication or a reoperation. Two (7%) of the twenty-eight subtrochanteric osteotomies were followed by nonunion. There was one instance of isolated loosening of the femoral stem. One acetabular component loosened, and one acetabular liner disengaged. Four hips dislocated postoperatively. All remaining components were well-fixed at the time of the last radiographic follow-up. No sciatic neurapraxic injuries were identified. CONCLUSIONS: Cementless total hip arthroplasty combined with a subtrochanteric femoral shortening osteotomy in patients with a high hip dislocation secondary to developmental dysplasia was associated with high rates of successful fixation of the implants and healing of the osteotomy site and a mean postoperative Harris hip score of 89 points. The complication rate, however, was substantially higher than that associated with primary total hip arthroplasty in patients with degenerative arthritis. LEVEL OF EVIDENCE: Therapeutic Level IV . See Instructions to Authors for a complete description of levels of evidence. ORIGINAL ABSTRACT CITATION: “Total Hip Arthroplasty with Shortening Subtrochanteric Osteotomy in Crowe Type-IV Developmental Dysplasia” (2009;91:2213-21).